Lung Cancer News

Atezolizumab as first-line monotherapy prolonged OS compared with chemotherapy alone for certain patients with non-small cell lung cancer, according to the agent’s manufacturer.

The FDA granted breakthrough therapy designation to tepotinib for treatment of patients with metastatic non-small cell lung cancer who harbor MET exon 14 skipping alterations and progressed after platinum-based cancer therapy.

The AMA implored the public to stop using e-cigarette s until health officials can determine the cause of e-cigarette-associated lung illnesses in the United States.

BARCELONA —STK11 and KEAP1 mutations appeared associated with poorer outcomes among patients with metastatic non-small cell lung cancer regardless of treatment with chemotherapy or immunotherapy, according to results of an exploratory analysis of the phase 3 MYSTIC trial presented at International Association for the Study of Lung Cancer World Conference on Lung Cancer.

BARCELONA — The combination of low-dose, weight-based ipilimumab and flat-dose nivolumab demonstrated safety and efficacy as first-line treatment for patients with stage IV non-small cell lung cancer and comorbidities that traditionally preclude them from enrolling in clinical trials, according to results of the single-arm, nonrandomized CheckMate 817 study presented at International Association for the Study of Lung Cancer World Conference on Lung Cancer.

BARCELONA — AMG 510 appeared well-tolerated and showed promising antitumor activity among patients with locally advanced or metastatic non-small cell lung cancer, with 96% of patients achieving disease control, according to phase 1 study results presented at International Association for the Study of Lung Cancer World Conference on Lung Cancer.

The FDA granted breakthrough therapy designation to capmatinib for first-line treatment of metastatic MET exon 14 skipping-mutated non-small cell lung cancer.

The addition of metformin hydrochloride to standard epidermal growth factor receptor tyrosine kinase inhibitors significantly improved PFS and OS among patients with advanced EGFR-mutated lung adenocarcinoma, according to randomized phase 2 study results published in JAMA Oncology.

Non-small cell lung cancer is associated with poorer prognosis and has a unique presentation in elderly patients with idiopathic pulmonary fibrosis, a recently published study showed

Heather A. Wakelee, MD, has been chosen president-elect of International Association for the Study of Lung Cancer.